title: Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for adult T cell leukemia/lymphoma (ATLL), but shows high mortality. We evaluated the feasibility of reduced-intensity transplantation using fludarabine and busulfan, with particular focus on the clinical impact of antithymocyte globulin (ATG) in the conditioning regimen. Fourteen elderly patients with aggressive ATLL were enrolled in the current study without ATG, and were compared to those in 15 patients who were treated similarly, but with ATG, in our previous study. Engraftment was prompt, and treatment was tolerable. Overall (OS) and progression-free survival (PFS) at 3 years were 36% and 31%, respectively. HTVL-1 proviral load became undetectable by the polymerase chain reaction in 62% of patients. Compared to the previous study with ATG, complete donor chimera was significantly delayed. Although early relapse tended to be decreased, OS or PFS was not improved significantly. Analysis of combined data from both our current and previous studies disclosed that grade I-II acute GVHD was the only factor that favorably affected OS and PFS. These data suggested the presence of a graft-versus-ATLL effect and the feasibility of a transplant procedure without ATG in elderly ATLL patients, but could not demonstrate the clinical benefit of incorporating ATG.
authors.affiliation: Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan. rtanosak@ncc.go.jp
authors.forename: Ryuji
authors.initials: R
authors.lastname: Tanosaki
authors.forename: Naokuni
authors.initials: N
authors.lastname: Uike
authors.forename: Atae
authors.initials: A
authors.lastname: Utsunomiya
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Saburi
authors.forename: Masato
authors.initials: M
authors.lastname: Masuda
authors.forename: Masao
authors.initials: M
authors.lastname: Tomonaga
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Eto
authors.forename: Michihiro
authors.initials: M
authors.lastname: Hidaka
authors.forename: Mine
authors.initials: M
authors.lastname: Harada
authors.forename: Ilseung
authors.initials: I
authors.lastname: Choi
authors.forename: Takeharu
authors.initials: T
authors.lastname: Yamanaka
authors.forename: Mari
authors.initials: M
authors.lastname: Kannagi
authors.forename: Masao
authors.initials: M
authors.lastname: Matsuoka
authors.forename: Jun
authors.initials: J
authors.lastname: Okamura
mesh_terms: D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005240:Feasibility Studies; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D015368:Human T-lymphotropic virus 1 / Q000302:isolation & purification; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy / Q000601:surgery* / Q000821:virology; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011533:Proviruses / Q000302:isolation & purification; D016019:Survival Analysis; D013601:T-Lymphocytes; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents